Comparative Pharmacology
Head-to-head clinical analysis: APRESAZIDE versus FENOLDOPAM MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRESAZIDE versus FENOLDOPAM MESYLATE.
APRESAZIDE vs FENOLDOPAM MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apresazide is a combination of hydralazine, a direct-acting vasodilator that relaxes arteriolar smooth muscle, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule.
Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.
1 capsule (hydralazine 25 mg / hydrochlorothiazide 25 mg) orally twice daily; may increase to 2 capsules twice daily if needed. Maximum: 4 capsules daily.
0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.
None Documented
None Documented
Hydralazine: 2-4 hours (fast acetylators), 4-8 hours (slow acetylators); Hydrochlorothiazide: 6-15 hours. Clinical context: Dosing interval typically 12 hours for hydralazine component.
Terminal elimination half-life approximately 10 minutes (range 5–20 min) in healthy adults; clinically, continuous infusion is required to maintain therapeutic effect due to rapid clearance.
Hydralazine: ~75% renal (metabolites), <10% unchanged; Hydrochlorothiazide: >95% renal (unchanged).
Renal (80% as metabolites, 10% as unchanged drug); fecal/biliary minor (10%)
Category C
Category C
Antihypertensive
Antihypertensive